Atai launches revixia life sciences to develop salvinorin a for a variety of mental health conditions

Berlin, aug. 12, 2021 (globe newswire) -- atai life sciences  (nasdaq: atai) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of revixia life sciences (revixia), a wholly owned subsidiary developing salvinorin a (sala) to treat a variety of mental health disorders.
ATAI Ratings Summary
ATAI Quant Ranking